Clinical context
Cataract surgery outcomes are not defined by best-corrected visual acuity alone. Refractive accuracy, vision at different distances, spectacle dependence, contrast sensitivity, dysphotopsia and procedural safety all matter. Corneal and macular status, capsular support, cataract density and IOL calculation also shape the final result. A statistically convincing average therefore still has to be interpreted against the characteristics of an individual eye.
What was studied
Recovery after phacoemulsification may differ with glaucoma, pseudoexfoliation or systemic disease, but isolated diagnoses poorly represent real-world multimorbidity. This retrospective Split University Hospital cohort analyzed 315 of 347 patients operated in November–December 2022 with at least one postoperative acuity measurement. Groups were: neither ocular nor systemic disease, 61; both, 59; systemic only, 182; ocular only, 13. Corneal status was qualitatively categorized as clear, hazy or showing Descemet folds.
How the evidence was produced
A cohort study describes how outcomes are associated with an exposure or treatment in an observed clinical population. This design is useful for routine practice, uncommon events and longer follow-up, but it remains vulnerable to confounding by indication, baseline risk differences and missing data. An association should not automatically be interpreted as a causal effect.
How to interpret the result
The data support closer early follow-up for ocular comorbidity, not pessimism about final benefit. Systemic disease alone did not show clear slowing. Yet the ocular-only group had just 13 patients, making effect size imprecise. Narrowing differences may reflect recovery, treatment, variable final-visit timing and missing observations.
The result should be understood as an estimate for the population studied, not a promise of an individual outcome. Statistical and clinical significance, absolute and relative effects, and prespecified and exploratory analyses should be distinguished. When several endpoints or subgroups are reported, the prespecified primary endpoint for which the study was designed usually provides the most reliable inference.
Clinical applicability
This evidence is most useful as a basis for preoperative discussion and surgical planning. It helps identify which outcomes should be measured and which trade-offs should be explained to patients. The average effect should not be generalized to every IOL, technique or patient without checking eligibility criteria, surgeon experience, biometry, ocular comorbidity and duration of follow-up.
Limitations
Retrospective records, multiple surgeons and ten examining ophthalmologists introduced heterogeneity. Edema was qualitative without pachymetry or OCT, and final visits had no fixed timing. Ocular and systemic diseases were broad pooled categories. Small subgroups, missing acuity, multiplicity and low model R² limit causal interpretation. Verify absolute edema rates, baseline acuity, NSAID and steroid use, endothelial density, missing-data handling and timing sensitivity in the source.
Beyond the limitations acknowledged by the authors, confidence is affected by sample size, follow-up duration, missing data, choice of comparator and relevance of the outcomes to routine care. Uncommon complications may remain undetected even in a well-conducted study. External validity is reduced when participants, equipment or investigator expertise differ substantially from everyday settings.
What to verify in the source
In the full paper, verify the protocol, eligibility criteria, baseline group characteristics, primary endpoint definition, confidence intervals, adverse events and losses to follow-up. Funding, conflicts of interest, trial registration and consistency between the published analysis and the original plan deserve separate attention. The DOI or source link below provides access to the primary publication for this check.